Abiopharma

Immidiate Report

WMK Investors Have Opportunity to Join Weis Markets, Inc. Fraud Investigation with the Schall Law Firm

Immediate Report

EVTL Investors Have Opportunity to Join Vertical Aerospace Ltd. Fraud Investigation with the Schall Law Firm

SAN Investors Have Opportunity to Join Banco Santander, S.A. Fraud Investigation with the Schall Law Firm

BW Investors Have Opportunity to Join Babcock & Wilcox Enterprises, Inc. Fraud Investigation with the Schall Law Firm

YRD Investors Have Opportunity to Join Yiren Digital Ltd. Fraud Investigation with the Schall Law Firm

PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Trip.com Group Limited (TCOM) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity